Reduction in creatine metabolites in macrophages exposed to small molecule analogues of the anti-inflammatory parasitic worm product ES-62

Alanazi, S. and Doonan, J. and Lumb, F. E. and Alenzi, N. and Jabbar, S. and Al-Riyami, L. and Suckling, C. J. and Harnett, W. and Watson, D. G. (2024) Reduction in creatine metabolites in macrophages exposed to small molecule analogues of the anti-inflammatory parasitic worm product ES-62. Parasite Immunology, 46 (2). e13026. ISSN 0141-9838 (https://doi.org/10.1111/pim.13026)

[thumbnail of Alanazi-etal-PI-2024-Reduction-in-creatine-metabolites-in-macrophages]
Preview
 Text. Filename: Alanazi-etal-PI-2024-Reduction-in-creatine-metabolites-in-macrophages.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (3MB)| Preview

Abstract

ES-62, a protein secreted by Acanthocheilonema viteae, is anti-inflammatory by virtue of covalently attached phosphorylcholine (PC) residues and thus a library of drug-like small molecule analogues (SMAs) based on its PC moieties has been designed for therapeutic purposes. Two members, SMAs 11a and 12b, were previously found to suppress production of pro-inflammatory cytokines by mouse bone marrow-derived macrophages (BMMs) exposed to cytosine-phosphate-guanosine oligodeoxynucleotides (CpG), agonists for Toll-like receptor 9. In order to explore the mechanism of action underlying such activities, an untargeted mass spectrometry-based metabolomics screen was undertaken. Stimulation of BMMs with CpG produced significant metabolic changes relating to glycolysis and the TCA cycle but the SMAs had little impact on this. Also, the SMAs did not promote alterations in metabolites known to be associated with macrophage M1/M2 polarization. Rather, BMMs exposed to SMAs 11a or 12b prior to CpG treatment, or even alone, revealed downregulation of metabolites of creatine, a molecule whose major role is in the transport of high energy phosphate from the mitochondria to the cytosol. These data therefore provide insight into a possible mechanism of action of molecules with significant therapeutic potential that has not previously been described for parasitic worm products.

ORCID iDs

Alanazi, S., Doonan, J. ORCID logoORCID: https://orcid.org/0000-0001-6933-4840, Lumb, F. E. ORCID logoORCID: https://orcid.org/0000-0001-9742-5125, Alenzi, N., Jabbar, S., Al-Riyami, L., Suckling, C. J., Harnett, W. ORCID logoORCID: https://orcid.org/0000-0001-9545-9401 and Watson, D. G. ORCID logoORCID: https://orcid.org/0000-0003-1094-7604;
CORE (COnnecting REpositories)